Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allison Portnoy

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Vaccine|April 29, 2015
Costs of vaccine programs across 94 low- and middle-income countriesAllison Portnoy, Sachiko Ozawa, Simrun Grewal, et al.
Vaccine|February 2, 2024
Modelling the health and economic impacts ofM72/AS01<sub>E</sub> vaccination and BCG-revaccination: Estimates for South AfricaTom Sumner, Rebecca A Clark, Christinah Mukandavire, et al.
PLOS Global Public Health|April 3, 2026
Rebalancing power in infectious disease modelling: Toward inclusive and contextual approachesJustice Moses K Aheto, Megan Auzenbergs, Matthew J Ferrari, et al.
The Lancet. Global Health|March 16, 2023
Estimating national-level measles case-fatality ratios in low-income and middle-income countries: an updated systematic review and modelling studyAlyssa N Sbarra, Jonathan F Mosser, Mark Jit, et al.
Sexually Transmitted Diseases|March 11, 2017
Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in MozambiqueLeila A Haidari, Shawn T Brown, Dagna Constenla, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden settingEmily A Burger, Jean-François Laprise, Allison Portnoy, et al.
Preventive Medicine|July 25, 2021
Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validationAllison Portnoy, Kine Pedersen, Lill Trogstad, et al.
Preventive Medicine|March 8, 2021
Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysisAllison Portnoy, Kine Pedersen, Lill Trogstad, et al.
Vaccine|June 7, 2022
COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recoveryJaspreet Toor, Xiang Li, Mark Jit, et al.
The Lancet Regional Health. Southeast Asia|February 17, 2025
Estimating the potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling studyRebecca A Clark, Allison Portnoy, Chathika K Weerasuriya, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Vaccine|April 29, 2015
Costs of vaccine programs across 94 low- and middle-income countriesAllison Portnoy, Sachiko Ozawa, Simrun Grewal, et al.
Vaccine|February 2, 2024
Modelling the health and economic impacts ofM72/AS01<sub>E</sub> vaccination and BCG-revaccination: Estimates for South AfricaTom Sumner, Rebecca A Clark, Christinah Mukandavire, et al.
PLOS Global Public Health|April 3, 2026
Rebalancing power in infectious disease modelling: Toward inclusive and contextual approachesJustice Moses K Aheto, Megan Auzenbergs, Matthew J Ferrari, et al.
The Lancet. Global Health|March 16, 2023
Estimating national-level measles case-fatality ratios in low-income and middle-income countries: an updated systematic review and modelling studyAlyssa N Sbarra, Jonathan F Mosser, Mark Jit, et al.
Sexually Transmitted Diseases|March 11, 2017
Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in MozambiqueLeila A Haidari, Shawn T Brown, Dagna Constenla, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden settingEmily A Burger, Jean-François Laprise, Allison Portnoy, et al.
Preventive Medicine|July 25, 2021
Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validationAllison Portnoy, Kine Pedersen, Lill Trogstad, et al.
Preventive Medicine|March 8, 2021
Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysisAllison Portnoy, Kine Pedersen, Lill Trogstad, et al.
Vaccine|June 7, 2022
COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recoveryJaspreet Toor, Xiang Li, Mark Jit, et al.
The Lancet Regional Health. Southeast Asia|February 17, 2025
Estimating the potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling studyRebecca A Clark, Allison Portnoy, Chathika K Weerasuriya, et al.
Pageof 9